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Background: Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control.
The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with
multiple myeloma.
Methods: We conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib
(1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m2 intravenously 1, 8, 15, and 22 of every 35-day cycle)
and dexamethasone.
Results: The median time to progression, progression free survival time, and overall survival time in the treatment groups
was 14.9, 14.9, and 38.3 months, respectively. The present study also suggests the possibility that the prognosis of patients
with high levels of AST and LDH might be worse.
Conclusions: Our results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is
feasible.
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Multiple myeloma is a plasma cell neoplasm that accounts
for approximately 10% of all hematologic malignancies [1].
A diagnosis of myeloma requires the presence of 10% or
more clonal plasma cells on bone marrow examination
and/or a biopsy-proven plasmacytoma, as well as evidence
of end-organ damage (i.e., hypercalcemia, renal insuffi-
ciency, anemia, or bone lesions) that is attributable to the
underlying plasma cell disorder [2]. The treatment of mul-
tiple myeloma (MM) is evolving rapidly [3]. There are at
least five active classes of treatment: alkylators (e.g., mel-
phalan and cyclophosphamide), corticosteroids (e.g., pred-
nisone and dexamethasone), proteasome inhibitors (e.g.,
bortezomib and carfilzomib), immunomodulatory drugs
(e.g., thalidomide and lenalidomide), and anthracyclines* Correspondence: kibat@kure-nh.go.jp
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unless otherwise stated.(e.g., doxorubicin and liposomal doxorubicin). Melphalan-
prednisone (MP) was introduced for the treatment of MM
in the late 1960s. In the subsequent 30 years, treatment im-
provements remained stagnant, since more complex chemo-
therapy combinations, such as vincristine, doxorubicin, and
dexamethasone (VAD), or with the addition of BCNU
(VBAD) or melphalan and cyclophosphamide (VCMP), only
led to small increases in the overall response rate but with-
out differences in survival, as assessed in a large meta-
analysis that included over 6,000 patients. The next step for-
ward was the use of high-dose melphalan followed by stem
cell support (autologous stem cell transplant - ASCT) for
young myeloma patients, which resulted in a significant im-
provement in progression-free survival and overall survival.
However, for elderly patients, MP remained the standard of
care. From the year 2000, a revolution in the treatment
armamentarium of MM has emerged with the availability of
new agents with a singular mechanism of action such as
thalidomide and lenalidomide, both immunomodulatory
drugs, and the proteasome inhibitor bortezomib [4]. A. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have been studied for the treatment of newly diagnosed
myeloma. Although randomized trials have been conducted
comparing older regimens such as MP with newer regimens
containing drugs such as thalidomide, lenalidomide, or bor-
tezomib, there are few if any randomized trials that have
compared modern combinations with each other. Even in
the few trials that have done so, definitive overall survival or
patient-reported quality-of-life differences have not been
demonstrated. Therefore, there is marked heterogeneity in
how newly diagnosed patients with myeloma are treated
around the world. The choice of initial therapy is often dic-
tated by availability of drugs, age and comorbidities of the
patient, and assessment of prognosis and disease aggressive-
ness [3].
In the present study, we retrospectively analyzed the
efficacy and safety of bortezomib and dexamethasone in
the treatment of patients with MM treated at the Na-
tional Hospital Organization Kure Medical Center and
Chugoku Cancer Center. The prognostic factor for sur-
vival in MM patients receiving bortezomib was also
retrospectively investigated in this study using Cox re-
gression analysis. In addition, the current status of stud-




Only demographic data of patients were stored in the
hospital database to enable retrieval of files manually
based on patient codes. Charts and discharge summaries
were perused. The study was investigated in accordance
with the ethical principles stated in the most recent ver-
sion of the Declaration of Helsinki or the applicable
guidelines on epidemiological studies issued by the
Ministry of Health, Labor and Welfare and the Ministry
of Education, Culture, Sports, Science and Technology,
Japan, whichever represented the greater protection to
the individual (http://www.mhlw.go.jp/). All data were
anonymously analysed without individual patient con-
sent due to the retrospective nature of the study. In
addition, the National Hospital Organization Kure
Medical Center and Chugoku Cancer Center Institu-
tional Review Board Ethics Committee waived the need
for individual informed consent and approved the study
(Approval Number G25-03, date 10/29/13).
Patients
We conducted a retrospective study of 44 patients
treated with bortezomib and dexamethasone therapy be-
tween March 2008 and October 2012. All patients who
had received at least one cycle of treatment that in-
cluded bortezomib were analyzed in this retrospective
study. The diagnosis of MM was confirmed using theInternational Myeloma Working Group (IMWG) criteria
[5]. In the present study, we did not collect data on the
patients diagnosed with plasma cell leukemia. Table 1
shows the characteristics of the 44 patients just before
the bortezomib therapy. The clinical stage was deter-
mined by the Durie-Salmon classification and the Inter-
national Staging System (ISS) [6,7]. The median age was
71 years old (49–86 years old), with 19 males and 25 fe-
males. Most (72.7%) had IgG or IgA myeloma. Fifteen
(34.1%) received autologous stem-cell transplantation.
Treatment
Forty-four patients were treated with bortezomib alone
(1.3 mg/m2 intravenously 1, 4, 8, and 11 of every 21-day
cycle or 1.3 mg/m2 intravenously 1, 8, 15, and 22 of
every35-day cycle) in combination with dexamethasone.
All patients received 8 or 16 mg of dexamethasone on
the day of and the day after each of bortezomib. In cases
of grade 3/4 hematological toxicity, the next chemother-
apy schedule was delayed until there was a sufficient
recovery of neutrophils or platelets. The dose of borte-
zomib would also be reduced according to the package
insert (from 1.3 mg/m2to 1.0 mg/m2, from 1.0 mg/m2 to
0.7 mg/m2, from 0.7 mg/m2 to stopping dosage, respect-
ively) in the subsequent cycles. In cases of grade 1/2
neuropathic pain or peripheral neuropathy, the dose of
bortezomib would also be reduced according to the
package insert (from 1.3 mg/m2 to 1.0 mg/m2, from 1.0
mg/m2 to 0.7 mg/m2, respectively), while in cases of
grade 3/4, the next chemotherapy schedule was delayed
until there was a sufficient recovery in terms of these
side effects, and the dose would also be reduced accord-
ing to the package insert (to 1.0 mg/m2, once a week).
The median duration of follow-up was 17.5 months
(range 0.7-58.3 months) and the median number of
treatment cycles was 3 (range 1–14). Forty patients dis-
continued treatment because of complete response (CR)
with autologous stem-cell transplantation (5 cases:
11.4%), CR without stem-cell transplantation (1 case:
2.5%), progressive disease (PD) (27 cases: 67.5%), toxicity
(1 case 2.5%), and other reasons (6 cases: 15.0%)
(Table 2). Of the 27 patients who discontinued bortezo-
mib with PD, 20 (74.1%) received conventional chemo-
therapy (CED, EPOCH, MP, MPT, MCNU-VMP, RD,
ROAD, VAD, cyclophosphamide alone, DEX pulse, thal-
idomide, lenalidomide, and zoledronic acid), and 7 of 20
(35.0%), who had the above chemotherapy, received
stem-cell transplantation, and 7 received no additional
therapy. Also, 2 of 27 patients (7.4%) patients received
radiotherapy (Table 2).
Assessments
Progression-free survival was defined as the time from the
initial administration of bortezomib to the identification
Table 1 Patient characteristics (n = 44)












No secreted 1 (2.3)








No. genetic abnormalities of 13q deletion n (%)
Yes 6 (13.6)
No 38 (86.4)
No. of stem cell transplantation n (%)
Yes 15 (34.1)
No 29 (65.9)









Stem cell transplantation 5 (5.9)
CP 5 (5.9)
ROAD 4 (4.7)
Cyclophosphamide alone 3 (3.5)
DEX pulse 2 (2.4)
Table 1 Patient characteristics (n = 44) (Continued)
MD 2 (2.4)
INF α-MP 2 (2.4)
CAD 1 (1.2)
RD 1 (1.2)
CP: cyclophosphamide, prednisolone; CAD: cyclophosphamide, adriamycin,
dexamethasone; DEX pulse: dexamethasone pulse therapy; MD: melphalan,
dexamethasone; MP: melphalan, prednisolone; HDD: high dose
dexamethasone; INF α: Interferon Alpha, RD: lenalidomide, dexamethasone;
ROAD: MCNU, vincristine, melphalan, dexamethasone; VAD: vincristine,
adriamycin, dexamethasone.
*A regimen was defined as a single drug or combination therapy. Front-line
therapy could be composed of more than one regimen.
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progression was defined as the time from the initial admin-
istration of bortezomib to disease progression or to the ini-
tiation of other therapy. Overall survival was defined as the
time from the initial administration of bortezomib to death
of any cause. Responses were assessed according to the
IMWG uniform response criteria [8]. Briefly, a CR was de-
fined by the absence of monoclonal immunoglobulin (M
protein) in serum and urine, as confirmed by immunofixa-
tion and the disappearance of any soft tissue plasmacyto-
mas and less than 5% plasma cells in bone marrow. PD was
defined by any of the following: an increase of M protein in
serum (the absolute increase must be 0.5 g/dl) or urine
(the absolute increase must be 200 mg per 24 h) or more
than 25%, an increase in bone marrow plasma cells (the
absolute % must be more than 10%), new or increased bone
lesions or plasmacytomas, or new hypercalcemia. Adverse
events were assessed and graded according to National
Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/CTC
AE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Statistical analysis
Progression-free survival, time to disease progression,
and overall survival were analyzed with Kaplan-Meier
methods. To identify the prognostic factors independ-
ently associated with overall survival and progression-
free survival, and to estimate the hazard ratios, the Cox
proportional hazards model was applied. All statistical
analyses were performed using SPSS version 19.0 statis-




Nineteen males and 25 females with a median age of 71
years (range 49–86 years) were treated consecutively
with bortezomib. Table 1 shows baseline patient charac-
teristics and a summary for MM patients. Patients re-
ceived a median of 1 therapy (range 0–8) prior to
bortezomib retreatment and a median of 3 cycles of
Table 2 Reasons for discontinuation of treatment with bortezomib and dexamethasone (n = 40) and numbers of
patients, which had conventional therapy in patients who discontinued bortezomib and dexamethasone with PD
(n = 27)
1) No. of patients who discontinued therapy n (%) 40 (100)
- CR with autologous stem cell transplantation 5 (12.5)
- CR without stem cell transplantation 1 (2.5)
- PD 27 (67.5)
- toxicity 1 (2.5)
- other reasons 6 (15.0)
2) No. of patients who had conventional chemotherapy in 27 patients who discontinued bortezomib and dexamethasone with PD n (%) 27 (100)
- conventional chemotherapy with autologous stem cell transplantation 6 (22.2)
- conventional chemotherapy with autologous stem cell transplantation and radiotherapy 1 (3.7)
- conventional chemotherapy with radiotherapy 1 (3.7)
- conventional chemotherapy alone 12 (44.4)
- no additional therapy 7 (25.9)
CR: complete response; PD: progressive disease.
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1–6 cycles.
Efficacy
A total of 627 instances of chemotherapy were per-
formed with a median of 11.5 instance (range 3–56).
The median dose for these patients was 11.86 mg/m2.
The median overall survival time, progression-free sur-
vival, and time to progression of MM was 38.3 months
(95% CI: 29.0-47.5 months), 14.9 months (95% CI: 7.6-
22.2 months), 14.9 months (95% CI: 7.6-22.2 months),
respectively (Figures 1 and 2). Associations between
overall survival and progression-free survival and pa-
tient characteristics (age, gender, ECOG performance
status, Durie-Salmon stage, International Staging Sys-
tem (ISS) stage, type of M protein, genetic abnormalities0 8 16 24
Figure 1 Overall survival curves in bortezomib treated MM patients.of 13q deletion, stem cell transplantation, hematologic
and biochemical measurements, β2-microglobulin) were
analyzed. In the present study, we did not detected any
high risk marker including del(17p) and t(4;14) in the
treated patients. The t(4;14) translocation is undetect-
able by conventional cytogenetics. In general, t(4;14)
translocation is detected by interphase FISH. FISH test-
ing for MM is indicated in individuals who have been
diagnosed with MM based on bone-marrow cells, which
have the characteristics of morphology, cytochemical
staining, and immunophenotype. Univariate Cox regres-
sion analyses to determine prognostic factors associated
with overall survival revealed 13 features with p < 0.05:
age, performance status, stem cell transplantation, PLT,
PDW, MPV, PLCR, K, AST, LDH, BUN, creatinine, and
CRP (Table 3). Meanwhile, univariate Cox regression32     40      48       56       64
0 4 8 12 16 20 24
Figure 2 Progression-free survival curves in bortezomib treated MM patients.
Table 3 Results of univariate and multivariate Cox
regression analyses for overall survival (p < 0.05)
Features Hazard 95% CI p value
ratio for hazard ratio
Univariate Cox regression
Age 1.09 1.01-1.17 0.027
Performance status 1.82 1.01-3.25 0.045
Stem cell transplantation 0.25 0.07-0.89 0.033
PLT 0.91 0.83-0.99 0.033
PDW 1.26 1.02-1.56 0.031
MPV 1.87 1.16-3.02 0.010
PLCR 1.08 1.02-1.15 0.013
K 2.15 1.09-4.27 0.028
AST 1.02 1.00-1.041 0.017
LDH 1.01 1.00-1.012 0.005
BUN 1.05 1.03-1.08 0.000
Creatinine 1.31 1.02-1.69 0.032
CRP 1.28 1.06-1.55 0.009
Multivariate Cox regression
AST 10.6 1.01-112 0.049
LDH 1.17 1.01-1.36 0.039
195% CI for hazard ration of AST is exactly 1.004-1.043.
295% CI for hazard ration of LDH is exactly 1.002-1.010.
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progression-free survival revealed 11 features with p <
0.05: age, stem cell transplantation, RBC, HCT, RDW,
Na, LDH, albumin, globulin, albumin/globulin (AG) ra-
tio, and CRP (Table 4). The important prognostic fac-
tors determined by multivariate Cox regression analyses
associated with overall survival were two features: AST
and LDH (Table 3). The prognosis of patients with high
levels of AST or LDH was worse. The optimal cut-off
points according to these parameters were not determined,Table 4 Results of univariate Cox regression analyses for
progression free survival (p < 0.05)
Features Hazard 95% CI p value
ratio for hazard ratio
Univariate Cox regression
Age 1.06 1.01-1.11 0.026
Stem cell transplantation 0.42 0.19-0.97 0.042
RBC 0.99 0.98-1.00 0.014
HCT 0.87 0.78-0.97 0.013
RDW 1.07 1.02-1.13 0.010
Na 0.88 0.80-0.96 0.003
LDH 1.01 1.00-1.01 0.000
Albumin 0.40 0.17-0.94 0.035
Globulin 1.27 1.03-1.57 0.028
AG ratio 0.35 0.14-0.83 0.018
CRP 1.20 1.06-1.36 0.005
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study were small. Therefore, further studies are needed to
clarify the optional cut-off points. Meanwhile, the import-
ant prognostic factors determined by multivariate Cox re-
gression analyses associated with progression-free survival
were not detected.
Hepatic dysfunction was observed in 7 patients (15.9%).
These patients were serologically negative for hepatitis B
and C. Also, abdominal ultrasonography or computerized
tomography demonstrated that it was related to liver in-
volvement with MM (2 cases: 4.5%), fatty liver (2 cases:
4.5%), gallstone (1 cases: 2.3%), and postcholecystectomy
(2 cases: 4.5%), respectively.
Safety
All 44 patients were evaluated for toxicity using the
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. Hematologic toxicity was revers-
ible and manageable. Patients reported grade 3/4 anemia
(13.6%), grade 3/4 neutropenia (15.9%), and grade 3/4
thrombocytopenia (22.7%) (Table 5). Although grade 4
neutropenia occurred, the patients were treated with
granulocyte colony-stimulating factors. Patients with
grade 3/4 anemia or grade 4 thrombocytopenia had
blood or platelet transfusions. The most common grade
3/4 nonhematologic toxicities were tumor lysis syn-
drome (6.8%). No treatment-related deaths were noted.
Interstitial pneumonitis, ileus, herpes zoster infections,
peripheral neuropathy, and fever were also observed. Be-
cause these toxicities were mild, bortezomib dose omis-
sion or reduction were rare.
Discussion
Multiple myeloma accounts for 10% of all hematologic
cancers [9]. With conventional treatments, MM remains
an essentially incurable disease with a median survival of
3–4 years [10]. Treatment of MM remains highly indi-
vidualized, with multiple factors that play a role in deter-
mining the best course of therapy. Patient-specific
criteria such as age of onset, whether the patient is
symptomatic at the time of diagnosis, and any detectedTable 5 All grade 3 and 4 adverse events (n = 44)
Adverse event Grade 3 Grade 4
N % N %
Anemia 5 11.4 1 2.3
Neutropenia 2 4.5 5 11.4
Thrombocytopenia 4 9.1 6 13.6
Tumor lysis syndrome 2 4.5 1 2.3
Interstitial pneumonitis 1 2.3 0 0
Ileus 1 2.3 0 0
Herpes zoster infections 1 2.3 0 0high-risk cytogenic abnormalities are all considerations
when selecting a regimen. Bortezomib has been ap-
proved by the Swiss Agency for Therapeutic Products
(Swissmedic, https://www.swissmedic.ch/) for the treat-
ment of MM in the frontline setting in combination with
MP and in patients with relapsed/refractory MM who
have received at least one prior therapy [11]. Bortezomib
offers a novel approach to the treatment of MM in
Phase 2 or 3 clinical trials producing rapid control
[12-14]. The achievement of a complete or partial re-
sponse to bortezomib as a salvage treatment is associated
with a significantly longer survival [12]. Several studies of
single-agent bortezomib at doses of 1.3 mg/m2 as first-
line, or second-line or latter, therapy have median time to
progression ranging from 1.4 to 17.3 months, median
progression-free survival time ranging from 5.0 to 17.0
months, and median overall survival time from 14.6 to
29.8 months, in MM [12-22] (Table 6). Our median time
to progression of 14.9 months, median progression-free
survival time of 14.9 months, and median overall survival
time survival time of 38.3 months, in patients treated with
MM was also comparable to other trials of single-agent
therapy.
In this study, the factors significantly associated with
overall survival were AST and LDH levels in patients
with bortezomib. The present study also suggests the
possibility that the prognosis of patients with high levels
of AST and LDH might be worse than that of patients
with low levels of these parameters. The blood test for
AST is usually used to detect liver damage. A review of
869 cases of multiple myeloma seen at the Mayo Clinic
from 1960 through 1971 revealed that initial findings
was a palpable liver in 21% [23]. It was reported that ab-
normalities in liver function were characteristic, and out
of 37 cases of MM, serum level of AST was increased in
22 (59.5%) [24]. In the present study, as mentioned
above, hepatic dysfunction was observed in 7 patients
(15.9%). These patients were serologically negative for
hepatitis B and C. Also, abdominal ultrasonography or
computerized tomography demonstrated that it was re-
lated to liver involvement with MM, fatty liver, gallstone,
and postcholecystectomy. Therefore, there is a possibility
that the prognosis of patients with hepatic dysfunction
might be worse than that of patients without this. More-
over, Walz-Mattmüller, et al. [25] previously investigated
the incidence and pattern of liver involvement in liver spec-
imens from 25 cases of MM histologically and immunohis-
tochemically. Liver infiltration was found in 32% of MM
specimens. Moreover, diffuse, non-destructive infiltration
was most common, and the infiltration was mainly sinus-
oidal, and also, nodular infiltration was seen. Furthermore,
Oshima et al. [26] reported that hepatic invasion was
observed in 15 patients (28.8%) in 52 consecutively autop-
sied cases with MM, but among them, diffuse tumor

















Min et al. , 2007 1.3 mg/m2 twice Yes 2-4 21 12.1 NR NR
[15] weekly for 2
weeks in a 21-day
cycle
Corso A, et al. 1.3 mg/m2 on days Yes ≥ 2 61 5.6 5.4 14.6
2009 1, 4, 8, and 11 of a
[16] 21-day cycle
Ohguchi H, et al. 1.3 mg/m2on days Yes ≥ 2 40 8.7 NR NR
2009 1, 4, 8, and 11 of a
[17] 21-day cycle
Present study 1.3 mg/m2 on days Yes 1-9 44 14.9 14.9 38.3











1.3 mg/m2 on days Yes ≥ 2 202 7.0 NR 16.0




1.3 mg/m2twice Yes 2-8 26 11.0 NR NR




1.3 mg/m2 on days No 1 64 17.3 17.0 NR
2009 1, 4, 8, and 11 of a
[18] 21-day cycle
Phase III
Kane et al. 2006 1.3 mg/m2 on days Yes ≥ 2 333 6.2 5.7 NR
[19] 1, 4, 8, and 11 of a
21-day cycle
(4 doses) for up to
8 cycles, followed by
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Table 6 Activity of bortezomib in multiple myeloma (Continued)
Orlowskiet al.
2007
1.3 mg/m2 on days No ≥ 2 322 6.5 6.5 NR




1.3 mg/m2 on days No 2-4 333 1.4 NR 29.8
[21] 1, 4, 8, and 11
for eight 3-week
cycles, then on days






1.3 mg/m2 on days No ≥ 2 184 6.8 NR NR
2008 1, 4, 8, and 11 of a
[22] 21-day cycle
Figure in parentheses indicate percentages. NR = Not reported; OS = overall survival; PFS = progression-free survival; TTP: time to progression.
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8 patents (15.4%), and liver infiltration by MM was frequent
in patients with IgA-type myeloma. Consistent with this,
further investigation are needed to clarify the mechanism
of liver damage in MM patients, because AST was one of
the important prognostic factors determined by multivari-
ate Cox regression analyses associated with overall survival,
although in the present study, we did not obtain liver speci-
mens for all patients with liver dysfunction. On the other
hand, it was reported that high serum LDH is associated
with features of advanced disease and inferior survival in
multiple myeloma [27]. Therefore, we speculate that the
worse prognosis of patients with high levels of AST and
LDH might be associated with the advanced stages of dis-
eases of these MM patients.
Greipp et al. previously reported the association be-
tween higher Durie-Salmon stage or ISS stage and worse
outcome [7]. However, in the present study, our data did
not reveal a significant impact for a Durie-Salmon stage
or ISS stage. Staging a patient under the Durie-Salmon-
system requires results from a bone marrow biopsy,
bone survey, serum electrophoresis, and values for
haemoglobin, haematocrit and serum calcium, and
meanwhile, the ISS-stage utilizes a combination of
serum β2 microglobulin and serum albumin. Therefore,
we speculated that the association between a higher
Durie-Salmon stage or ISS stage and worse outcome was
not observed, because Durie-Salmon stage or ISS stage
did not correlate with high AST and LDH levels. Also,
consistent with this, several investigators reported the
prognostic value of LDH in MM patients [28,29], This,
however, was not incorporated in any widely usedstaging system, although its has an ability to identify pa-
tients with an especially adverse outcome [30,31]. Be-
cause the investigated patient numbers in the present
study were small, further investigations are also needed
to clarify this matter.
According to the issue that a high AST and LDH were
not associated with progression-free survival, since the
late 70s, the relationship between hematological malig-
nancies and elevated LDH has been intensively studied
[32]. In aggressive lymphoma patients, increased LDH
was found linked to high tumor burden and turnover
[33]. In patients that received autologous stem-cell
transplantation for multiple myeloma, a high LDH was
an independent prognostic factor for both overall sur-
vival and progression-free survival [34]. However, in the
present study, although LDH and AST had an independ-
ent prognostic value for overall survival, these were not
statistically significant indicators for progression-free
survival. This may be a reflection of inadequate sample
size.
The toxicity profile in our study was generally accept-
able (Table 5). The major toxicity was myelosuppression;
the incidence of grade 3/4 toxicity was 22.7% for
thrombocytopenia, 15.9% for neutropenia, 6.8% for
anemia, and 6.8% for tumor lysis syndrome. Although
grade 4 neutropenia occurred, the patients were treated
with granulocyte colony-stimulating factors. Patients
with grade 3/4 anemia or grade 4 thrombocytopenia had
blood or platelet transfusions. Treatment-related deaths
were not observed. Consistent with this, the first trial
was reported by Richardson et al. [12], who treated 193
patients with MM with bortezomib. Grade 3 adverse
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fatigue (in 12%), peripheral neuropathy (in 12%), and
neutropenia (in 11%), meanwhile, grade 4 events
(thrombocytopenia, neutropenia, vomiting, diarrhea,
weakness) occurred in 14 percent of patients; otherwise,
no severe adverse events occurred.
In conclusion, recent clinical studies, including this
study, demonstrate that bortezomib has a therapeutic ef-
fect on MM. This study also suggests that bortezomib
and dexamethasone are well tolerated in the treatment
of MM. In the present study, we have documented the
strengths of the study that there is a possibility that the
prognosis of patients with high levels of AST and LDH
might be worse than the prognosis of patients with low
levels of AST and LDH. According to the weakness of
this study, although AST and LDH had independent
prognostic value for overall survival, we did not demon-
strate that these were statistically significant indicators
for progression-free survival. This may be a reflection of
inadequate sample size. The presented study is a retro-
spective study, and therefore, these results should be
confirmed in further prospective studies.
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